For comparison: A2M: mraket cap: $7.3b, 2018 Infant formula revenue: ~A$720m, EBITDA/Revenue: ~30% BAL: market cap: $1.1b, 2018 Infant formula revenue: ~A$300m, EBITDA/Revenu: ~21%